Analysts Weigh In on Exelixis' Approval Decision (Updated) |
![]() |
![]() |
By Staff and Wire Reports | |
Monday, 26 November 2012 15:46 | |
![]() Analysts from four large firms who have been following the story list the odds for Cabozantinib's approval as follows:
Published reports have Holtorf Medical Group's Dr. Kent Holtorf stating that the clinical data looked "very reassuring" and more promising for patients than any other alternatives. He notes that it will be exciting for physician's, which will now be able to offer something to patients upon approval. Exelixis shares traded mostly sideways during today's mixed market, but have seen a surge in recent weeks leading up to this decision. Update: Lazard's biotechnology analyst is Ryan Martins "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |